

REGISTERED NUMBER: 01794026 (England and Wales)

Molecular Dimensions Limited
Group Strategic Report,
Directors' Report and
Consolidated Financial Statements
for the Year Ended 31 December 2022

SA WEDNESDAY



ACZSSCXT

A09	27/03/2024	#121
COMPANIES HOUSE		
	ACY1HTSZ	
A10	02/03/2024	#269
COMPANIES HOUSE		

Molecular Dimensions Limited (Registered number: 01794026)

**Contents of the Consolidated Financial Statements
for the year ended 31 December 2022**

	Page
Company Information	1
Group Strategic Report	2
Directors' Report	3
Independent Auditors' Report	5
Consolidated Income Statement	8
Consolidated Other Comprehensive Income	9
Consolidated Balance Sheet	10
Company Balance Sheet	11
Consolidated Statement of Changes in Equity	12
Company Statement of Changes in Equity	13
Consolidated Cash Flow Statement	14
Notes to the Consolidated Financial Statements	15

Molecular Dimensions Limited
Company Information
for the year ended 31 December 2022

Directors:

B R Travis
B M Wall
Ms J A Heidinger
J M Allan

Registered office:

Unit 5a - Calibre Scientific House
R-Evolution@The Advanced Manufacturing
Park, Selden Way, Catcliffe,
Rotherham
S60 5XA

Registered number:

01794026 (England and Wales)

Auditors:

Cooper Parry Group Limited
Statutory Auditor
New Derwent House
69-73 Theobalds Road
London
WC1X 8TA

Molecular Dimensions Limited (Registered number: 01794026)

**Group Strategic Report
for the year ended 31 December 2022**

The directors present their strategic report of the company and the group for the year ended 31 December 2022.

Principal activities and review of the business

Molecular Dimensions Limited (the 'Company') is the UK parent of companies (the 'Group') within the Calibre Scientific Group, a US based, private equity funded, group of companies. The principal activities of the Company and its UK subsidiaries are to supply and distribute modern crystallisation screens, reagents, consumables, tools, equipment and instrumentation to worldwide research and development organisations and hospitals within Life Sciences and similar sectors.

The US parent is very acquisitive, and the UK Group has expanded significantly during the period of this report and the subsequent period.

Principal risks and uncertainties

The Group's principal risks and uncertainties relate to the impact of the global economy on medical research and development and how investment constraints affect customers spending. Generally, the Life Sciences sector is quite resilient with COVID having produced significant opportunity as well as producing uncertainty in the way customers operate.

Key performance indicators

The Group's key financial and other performance indicators during the year were as follows:

	2022 £'000	2021 £'000	Change £'000
Revenue	22,791	20,549	2,242
Gross Profit	9,036	7,239	1,797
Gross Profit %	39.6%	35.2%	
Administrative Expenses	(9,818)	(3,768)	(6,119)

The Group revenue for the year increased to £22,791,361 (2021 - £20,548,995). 2022 saw a significant fall in revenue relating to COVID-19, however revenue growth was achieved through business acquisition, with the full year impact of the 2021 acquisition of Elkay Laboratory Products (UK) Ltd and Medline Scientific Ltd and the acquisition in the second half of 2022 of Agar Scientific Ltd.

Gross profit for the year increased to £9,035,679 (2021 - £7,238,952). The gross profit percentage increased to 39.6% (2021 - 35.2%). This was a result of product mix with an increase in manufactured product and niche high margin distribution from Agar Scientific Ltd and a reduction in low margin COVID-19 related products.

Administrative expenses increased significantly to £9,818,306 (2021 - £3,768,336), reflecting increased back-office costs that result from the acquisition process and expansion of the business. In addition, the group has seen an increase in central administration costs to create an organisational structure to support future acquisitions and drive synergistic opportunities.

War in Ukraine

As a result of the conflict beginning in February 2022 between Russia and Ukraine the company has reviewed its operations to assess the potential impact on the business. Other than the impact of the general economic changes resulting from the war the Company has concluded that the conflict has no material impact on the operation of the business.

On behalf of the board:

B R Travis

.....
B R Travis - Director

Mar 1, 2024

Date:

Molecular Dimensions Limited (Registered number: 01794026)

**Directors' Report
for the year ended 31 December 2022**

The directors present their report with the financial statements of the company and the group for the year ended 31 December 2022.

Dividends

No dividends will be distributed for the year ended 31 December 2022.

The loss for the year, after taxation, amounted to £1,257,945.

Future developments

The Calibre Scientific Group, a private equity owned group, based in the US, is highly acquisitive in achieving its growth strategy. Molecular Dimensions Limited, acting as the UK parent entity for the Group, is therefore subject to rapid growth and organisational change as new acquisitions are identified. This has led to the development of a more regional management structure within Molecular Dimensions Limited to ensure that the growing organisation is more effective and efficient in its operations.

Events since the end of the year

Information relating to events since the end of the year is given in the notes to the financial statements.

Directors

The directors shown below have held office during the whole of the period from 1 January 2022 to the date of this report.

B R Travis

B M Wall

Other changes in directors holding office are as follows:

Ms J A Heidinger and J M Allan were appointed as directors after 31 December 2022 but prior to the date of this report.

Statement of directors' responsibilities

The directors are responsible for preparing the Group Strategic Report, the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement as to disclosure of information to auditors

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

Molecular Dimensions Limited (Registered number: 01794026)

**Directors' Report
for the year ended 31 December 2022**

Auditors

The auditors, Cooper Parry Group Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

On behalf of the board:

B R Travis

.....
B R Travis - Director

Mar 1, 2024

Date:

Independent Auditors' Report to the Members of Molecular Dimensions Limited

Opinion

We have audited the financial statements of Molecular Dimensions Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2022 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and of the parent company affairs as at 31 December 2022 and of the group's loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Directors' Report, but does not include the financial statements and our Auditors' Report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Group Strategic Report and the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Directors' Report have been prepared in accordance with applicable legal requirements.

**Independent Auditors' Report to the Members of
Molecular Dimensions Limited**

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Directors' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the company and the industry in which it operates, and considered the risk of acts by the company that were contrary to applicable laws and regulations, including fraud. We discussed with the Directors the policies and procedures in place regarding compliance with laws and regulations. We discussed amongst the audit team the identified laws and regulations, and remained alert to any indications of non-compliance.

During the audit we focused on laws and regulations which could reasonably be expected to give rise to a material misstatement in the financial statements, including, but not limited to, the Companies Act 2006 and UK tax legislation. Our tests included agreeing the financial statement disclosures to underlying supporting documentation and enquiries with management.

Our procedures in relation to fraud included but were not limited to: inquires of management whether they have any knowledge of any actual, suspected or alleged fraud, and discussions amongst the audit team regarding risk of fraud such as opportunities for fraudulent manipulation of financial statements. We determined that the principal risks related to posting manual journal entries to manipulate financial performance and management bias through judgements in accounting estimates. We also addressed the risk of management override of internal controls, including testing journals and evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.

**Independent Auditors' Report to the Members of
Molecular Dimensions Limited**

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. In assessing the potential risks of material misstatement we obtained an understanding of; the entities operations, including the nature of its revenue sources and services and of its objectives and strategies to understand the classes of transactions, account balances, expected financial statement disclosures and business risks that may result in risks of material misstatement. We did not identify any matters relating to non-compliance with laws and regulations relating to fraud.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Cooper Parry Group Limited

Gary Staunton (Senior Statutory Auditor)
for and on behalf of Cooper Parry Group Limited
Statutory Auditor
New Derwent House
69-73 Theobalds Road
London
WC1X 8TA

Date: 1/3/2024

Molecular Dimensions Limited (Registered number: 01794026)

Consolidated
Income Statement
for the year ended 31 December 2022

	Notes	2022 £	2021 £
Turnover	3	22,791,361	20,548,995
Cost of sales		<u>(13,755,682)</u>	<u>(13,310,043)</u>
Gross profit		9,035,679	7,238,952
Administrative expenses		<u>(9,818,306)</u>	<u>(3,768,336)</u>
Operating (loss)/profit	5	(782,627)	3,470,616
Interest receivable and similar income	6	<u>2,978</u>	<u>4</u>
		(779,649)	3,470,620
Interest payable and similar expenses	7	<u>(1,528)</u>	<u>(109,087)</u>
(Loss)/profit before taxation		(781,177)	3,361,533
Tax on (loss)/profit	8	<u>(476,768)</u>	<u>(999,123)</u>
(Loss)/profit for the financial year		<u>(1,257,945)</u>	<u>2,362,410</u>
(Loss)/profit attributable to: Owners of the parent		<u>(1,257,945)</u>	<u>2,362,410</u>

The notes form part of these financial statements

Molecular Dimensions Limited (Registered number: 01794026)

Consolidated
Other Comprehensive Income
for the year ended 31 December 2022

	Notes	2022 £	2021 £
(Loss)/profit for the year		(1,257,945)	2,362,410
Other comprehensive income		-	-
Total comprehensive income for the year		<u>(1,257,945)</u>	<u>2,362,410</u>
Total comprehensive income attributable to: Owners of the parent		<u>(1,257,945)</u>	<u>2,362,410</u>

The notes form part of these financial statements

Molecular Dimensions Limited (Registered number: 01794026)

Consolidated Balance Sheet
31 December 2022

	Notes	£	2022 £	£	2021 £
Fixed assets					
Intangible assets	10		14,981,772		6,885,073
Tangible assets	11		2,557,985		1,079,849
Investments	12		-		-
			<u>17,539,757</u>		<u>7,964,922</u>
Current assets					
Stocks	13	3,729,641		2,731,336	
Debtors	14	5,135,185		6,026,662	
Cash at bank		<u>1,924,146</u>		<u>1,610,643</u>	
		10,788,972		10,368,641	
Creditors					
Amounts falling due within one year	15	<u>5,658,431</u>		<u>12,597,045</u>	
Net current assets/(liabilities)			<u>5,130,541</u>		<u>(2,228,404)</u>
Total assets less current liabilities			<u>22,670,298</u>		<u>5,736,518</u>
Creditors					
Amounts falling due after more than one year	16		(18,167,919)		(17,177)
Provisions for liabilities	18		<u>(155,201)</u>		<u>(114,218)</u>
Net assets			<u>4,347,178</u>		<u>5,605,123</u>
Capital and reserves					
Called up share capital	19		30		30
Share premium			70		70
Other reserves			237,835		237,835
Retained earnings			<u>4,109,243</u>		<u>5,367,188</u>
Shareholders' funds			<u>4,347,178</u>		<u>5,605,123</u>

The financial statements were approved by the Board of Directors and authorised for issue onMar.1, 2024..... and were signed on its behalf by:

B R Travis

.....
B R Travis - Director

The notes form part of these financial statements

Molecular Dimensions Limited (Registered number: 01794026)

Company Balance Sheet
31 December 2022

	Notes	£	2022 £	£	2021 £
Fixed assets					
Intangible assets	10		3,539,261		3,226,578
Tangible assets	11		2,233,766		984,495
Investments	12		<u>19,036,270</u>		<u>7,837,681</u>
			24,809,297		12,048,754
Current assets					
Stocks	13	1,646,817		1,598,255	
Debtors	14	3,115,475		2,894,435	
Cash at bank		<u>581,416</u>		<u>496,495</u>	
		5,343,708		4,989,185	
Creditors					
Amounts falling due within one year	15	<u>8,665,908</u>		<u>11,230,224</u>	
Net current liabilities			<u>(3,322,200)</u>		<u>(6,241,039)</u>
Total assets less current liabilities			21,487,097		5,807,715
Creditors					
Amounts falling due after more than one year	16		(16,406,491)		-
Provisions for liabilities	18		<u>(108,953)</u>		<u>(108,953)</u>
Net assets			<u>4,971,653</u>		<u>5,698,762</u>
Capital and reserves					
Called up share capital	19		30		30
Share premium			70		70
Other reserves			237,835		237,835
Retained earnings			<u>4,733,718</u>		<u>5,460,827</u>
Shareholders' funds			<u>4,971,653</u>		<u>5,698,762</u>
Company's (loss)/profit for the financial year			<u>(727,109)</u>		<u>6,946,248</u>

The financial statements were approved by the Board of Directors and authorised for issue on Mar 1, 2024 and were signed on its behalf by:

B R Travis
B R Travis - Director

The notes form part of these financial statements

Molecular Dimensions Limited (Registered number: 01794026)

Consolidated Statement of Changes in Equity
for the year ended 31 December 2022

	Called up share capital £	Retained earnings £	Share premium £	Other reserves £	Total equity £
Balance at 1 January 2021	30	3,004,778	70	237,835	3,242,713
Changes in equity					
Total comprehensive income	-	2,362,410	-	-	2,362,410
Balance at 31 December 2021	30	5,367,188	70	237,835	5,605,123
Changes in equity					
Total comprehensive income	-	(1,257,945)	-	-	(1,257,945)
Balance at 31 December 2022	30	4,109,243	70	237,835	4,347,178

The notes form part of these financial statements

Molecular Dimensions Limited (Registered number: 01794026)

Company Statement of Changes in Equity
for the year ended 31 December 2022

	Called up share capital £	Retained earnings £	Share premium £	Other reserves £	Total equity £
Balance at 1 January 2021	30	(1,485,421)	70	237,835	(1,247,486)
Changes in equity					
Total comprehensive income	-	6,946,248	-	-	6,946,248
Balance at 31 December 2021	30	5,460,827	70	237,835	5,698,762
Changes in equity					
Total comprehensive income	-	(727,109)	-	-	(727,109)
Balance at 31 December 2022	30	4,733,718	70	237,835	4,971,653

The notes form part of these financial statements

Molecular Dimensions Limited (Registered number: 01794026)

Consolidated Cash Flow Statement
for the year ended 31 December 2022

	Notes	2022 £	2021 £
Cash flows from operating activities			
Cash generated from operations	23	14,921,483	4,946,412
Interest paid		(1,528)	(109,087)
Tax paid		(871,641)	(809,766)
Net cash from operating activities		<u>14,048,314</u>	<u>4,027,559</u>
Cash flows from investing activities			
Purchase of intangible fixed assets		(462,238)	(217,503)
Purchase of tangible fixed assets		(2,343,348)	(836,294)
Net cash inflow/(outflow) on acquisition		(10,932,203)	1,167,114
Interest received		<u>2,978</u>	<u>4</u>
Net cash from investing activities		<u>(13,734,811)</u>	<u>113,321</u>
Cash flows from financing activities			
Loan repayments in year		-	(3,000,000)
Capital repayments in year		-	(12,304)
Net cash from financing activities		<u>-</u>	<u>(3,012,304)</u>
Increase in cash and cash equivalents		<u>313,503</u>	<u>1,128,576</u>
Cash and cash equivalents at beginning of year	24	<u>1,610,643</u>	<u>482,067</u>
Cash and cash equivalents at end of year	24	<u><u>1,924,146</u></u>	<u><u>1,610,643</u></u>

The notes form part of these financial statements

**Notes to the Consolidated Financial Statements
for the year ended 31 December 2022**

1. Statutory information

Molecular Dimensions Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

2. Accounting policies

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The financial statements are presented in sterling which is the functional currency of the group and rounded to the nearest £.

Basis of consolidation

The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

The consolidated financial statements incorporate the results of business combinations using the purchase method. In the Consolidated Statement of Financial Position, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated Statement of Comprehensive Income and retained earnings from the date on which control is obtained. They are deconsolidated from the date control ceases.

The subsidiaries Protein Ark Limited, BioServ UK Limited, Kalon Biological Limited, Lorne Laboratories Limited, Elkay Laboratory Products (UK) Limited, Medline Scientific Limited, Technival group limited, Technival limited, Anville Instruments limited, Agar international limited and Agar scientific limited have claimed exemption from audit under the provisions of section 479A of the Companies Act 2006. Molecular Dimensions Limited has provided a guarantee over these subsidiaries' liabilities under section 479C of the Act.

Going concern

The financial statements have been prepared on a going concern basis. The Directors have reviewed and considered relevant information, including the annual budget and future cash flows in making their assessment. Based on these assessments, the Directors have concluded that they can continue to adopt the going concern basis in preparing the annual report and accounts.

2. Accounting policies - continued

Significant judgements and estimates

Preparation of the financial statements requires management to make significant judgements and estimates in determining the carrying amounts of certain assets and liabilities. Management makes assumptions of the effects of uncertain future events on those assets and liabilities at the balance sheet date. The Preparation of the financial statements requires management to make significant judgements and estimates in determining the carrying amounts of certain assets and liabilities. Management makes assumptions of the effects of uncertain future events on those assets and liabilities at the balance sheet date. The management's estimates and assumptions are based on historical experience and expectation of future events and are reviewed periodically. This disclosure excludes uncertainty over future events and judgement in respect of measuring financial instruments.

The group engages in projects which can take many years to complete. The directors therefore must make estimations in terms of the level of revenue to recognise within each set of annual financial statements. Such estimations are by their nature judgemental but are backed by reviews of correspondence and resourcing forecasts performed post year end.

There is estimation uncertainty in calculating bad debt provisions. A full line by line review of trade debtors is carried out at the end of each month. Whilst every attempt is made to ensure that the bad debt provisions are as accurate as possible, there remains a risk that the provision do not match the level of debts which ultimately prove to be uncollectable.

The company's tangible assets are depreciated on a straight line basis over their useful economic lives. Management reviews the appropriateness of assets' useful economic lives at least annually and any changes could affect prospective depreciation rates and asset carrying values.

Intangible assets are at cost less accumulated amortisation. Amortisation is charged on a straight line basis over the estimated economic life of the assets

2. Accounting policies - continued

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the Group and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Sale of goods

Turnover from the sale of goods is recognised when all of the following conditions are satisfied:

- the Group has transferred the significant risks and rewards of ownership to the buyer;
- the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- the amount of turnover can be measured reliably;
- it is probable that the Group will receive the consideration due under the transaction; and
- the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Turnover from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:

- the amount of turnover can be measured reliably;
- it is probable that the Group will receive the consideration due under the contract;
- the stage of completion of the contract at the end of the reporting period can be measured reliably; and
- the costs incurred and the costs to complete the contract can be measured reliably.

Goodwill

Goodwill represents the excess of the cost of a business combination over the fair value of the group's share of the net identifiable assets of the acquired subsidiary at the date of acquisition. Goodwill on acquisitions of subsidiaries is included in 'intangible assets'.

For business combinations occurring after 1 January 2019, intangible assets acquired are recognised separately from goodwill only when they are separable from the acquired entity and give rise to other contractual/legal rights. Prior to 1 January 2019 intangible assets acquired were recognised separately from goodwill when they were separable from the acquired entity or gave rise to other contractual/legal rights.

Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. Goodwill is carried at cost less accumulated amortisation and accumulated impairment losses. Goodwill amortisation is calculated by applying the straight-line method to its estimated useful life. If a reliable estimate cannot be made, the useful life of goodwill is presumed to be 10 years. Goodwill is being amortised to 'administrative expenses' over 10 years.

Estimates of the useful economic life of goodwill are based on a variety of factors such as the expected use of the acquired business, the expected useful life of the cash generating units to which the goodwill is attributed, any legal, regulatory or contractual provisions that can limit useful life and assumptions that market participants would consider in respect of similar businesses.

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

The estimated useful lives range as follows:

Computer Software - amortised over useful life once operational
Development costs - amortised over remaining lease term

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

2. Accounting policies - continued

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Freehold property	- Straight line over the life of the lease
Plant and machinery	- 25% on cost
Fixtures and fittings	- 25% on cost
Motor vehicles	- 25% on cost
Computer equipment	- 25% on cost

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants of a revenue nature are recognised in the Consolidated Statement of Comprehensive Income in the same period as the related expenditure.

Stocks

Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in the Consolidated Statement of Comprehensive Income.

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

Financial instruments

Financial assets and financial liabilities are recognised in the balance sheet when the company becomes a party to the contractual provisions of the instrument.

Trade and other debtors and creditors are classified as basic financial instruments and measured at initial recognition at transaction price. Debtors and creditors are subsequently measured at amortised cost using the effective interest rate method. A provision is established when there is objective evidence that the company will not be able to collect all amounts due.

Cash and cash equivalents are classified as basic financial instruments and comprise cash in hand and at bank and bank overdrafts which are an integral part of the company's cash management.

Financial liabilities and equity instruments issued by the company are classified in accordance with the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Molecular Dimensions Limited (Registered number: 01794026)

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

2. Accounting policies - continued

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years. If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

The assets of the plan are held separately from the Group in independently administered funds

3. Turnover

The turnover and loss (2021 - profit) before taxation are attributable to the one principal activity of the group.

An analysis of turnover by class of business is given below:

	2022	2021
	£	£
Sales	22,637,984	20,380,041
Other	153,377	168,954
	<u>22,791,361</u>	<u>20,548,995</u>

An analysis of turnover by geographical market is given below:

	2022	2021
	£	£
United Kingdom	12,232,862	12,864,986
Europe	5,068,533	3,942,553
Rest of the world	5,489,966	3,741,456
	<u>22,791,361</u>	<u>20,548,995</u>

Molecular Dimensions Limited (Registered number: 01794026)

**Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022**

4. Employees and directors

	2022	2021
	£	£
Wages and salaries	4,291,062	2,319,985
Social security costs	481,124	214,620
Other pension costs	<u>136,292</u>	<u>107,214</u>
	<u>4,908,478</u>	<u>2,641,819</u>

The average number of employees during the year was as follows:

	2022	2021
Employees	<u>109</u>	<u>56</u>

	2022	2021
	£	£
Directors' remuneration	<u>229,051</u>	<u>175,692</u>

Information regarding the highest paid director for the year ended 31 December 2022 is as follows:

	2022
	£
Emoluments etc	<u>229,051</u>

5. Operating (loss)/profit

	2022	2021
	£	£
Depreciation	254,459	84,017
Amortisation	1,639,374	418,327
Auditors' remuneration	70,000	70,340
Foreign exchange differences	<u>192,737</u>	<u>(23,876)</u>

6. Interest receivable and similar income

	2022	2021
	£	£
Deposit account interest	<u>2,978</u>	<u>4</u>

7. Interest payable and similar expenses

	2022	2021
	£	£
Interest payable	<u>1,528</u>	<u>109,087</u>

8. Taxation

Analysis of the tax charge

The tax charge on the loss for the year was as follows:

	2022	2021
	£	£
Current tax:		
UK corporation tax	470,120	918,172
Deferred tax	<u>6,648</u>	<u>80,951</u>
Tax on (loss)/profit	<u>476,768</u>	<u>999,123</u>

Molecular Dimensions Limited (Registered number: 01794026)

**Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022**

8. Taxation - continued

Reconciliation of total tax charge included in profit and loss

The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

	2022	2021
	£	£
(Loss)/profit before tax	<u>(781,177)</u>	<u>3,361,533</u>
(Loss)/profit multiplied by the standard rate of corporation tax in the UK of 19% (2021 - 19%)	(148,424)	638,691
Effects of:		
Expenses not deductible for tax purposes	-	89,542
Adjustments to tax charge in respect of previous periods	132,631	131,833
Other adjustments	148,424	32,062
Impact of changes to tax rates on deferred tax	-	26,044
Profit making subsidiaries tax	337,489	-
Deferred tax movement	<u>6,648</u>	<u>80,951</u>
Total tax charge	<u>476,768</u>	<u>999,123</u>

9. Individual income statement

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.

10. Intangible fixed assets

Group

	Goodwill	Leasehold	Computer	Totals
	£	interest	software	£
		£	£	
Cost				
At 1 January 2022	7,488,174	41,134	386,819	7,916,127
Additions	<u>8,941,172</u>	<u>-</u>	<u>462,238</u>	<u>9,403,410</u>
At 31 December 2022	<u>16,429,346</u>	<u>41,134</u>	<u>849,057</u>	<u>17,319,537</u>
Amortisation				
At 1 January 2022	1,010,487	20,567	-	1,031,054
Amortisation for year	<u>1,195,876</u>	<u>-</u>	<u>110,835</u>	<u>1,306,711</u>
At 31 December 2022	<u>2,206,363</u>	<u>20,567</u>	<u>110,835</u>	<u>2,337,765</u>
Net book value				
At 31 December 2022	<u>14,222,983</u>	<u>20,567</u>	<u>738,222</u>	<u>14,981,772</u>
At 31 December 2021	<u>6,477,687</u>	<u>20,567</u>	<u>386,819</u>	<u>6,885,073</u>

Molecular Dimensions Limited (Registered number: 01794026)

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

10. Intangible fixed assets - continued

Company

	Goodwill £	Computer software £	Totals £
Cost			
At 1 January 2022	2,839,759	386,819	3,226,578
Additions	-	312,683	312,683
At 31 December 2022	<u>2,839,759</u>	<u>699,502</u>	<u>3,539,261</u>
Net book value			
At 31 December 2022	<u>2,839,759</u>	<u>699,502</u>	<u>3,539,261</u>
At 31 December 2021	<u>2,839,759</u>	<u>386,819</u>	<u>3,226,578</u>

11. Tangible fixed assets

Group

	Improvements to property £	Assets under construction £	Plant and machinery £	Motor vehicles £
Cost				
At 1 January 2022	1,845	815,158	281,293	61,291
Additions	2,583,319	-	629,081	132,855
Disposals	-	(815,158)	-	-
At 31 December 2022	<u>2,585,164</u>	<u>-</u>	<u>910,374</u>	<u>194,146</u>
Depreciation				
At 1 January 2022	1,827	-	172,791	4,147
Charge for year	673,375	-	492,261	89,008
Eliminated on disposal	-	-	-	-
At 31 December 2022	<u>675,202</u>	<u>-</u>	<u>665,052</u>	<u>93,155</u>
Net book value				
At 31 December 2022	<u>1,909,962</u>	<u>-</u>	<u>245,322</u>	<u>100,991</u>
At 31 December 2021	<u>18</u>	<u>815,158</u>	<u>108,502</u>	<u>57,144</u>

Molecular Dimensions Limited (Registered number: 01794026)

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

11. Tangible fixed assets - continued

Group

	Fixtures and fittings £	Office equipment £	Computer equipment £	Totals £
Cost				
At 1 January 2022	243,779	13,711	37,117	1,454,194
Additions	193,633	44,187	79,525	3,662,600
Disposals	-	-	-	(815,158)
At 31 December 2022	<u>437,412</u>	<u>57,898</u>	<u>116,642</u>	<u>4,301,636</u>
Depreciation				
At 1 January 2022	176,974	11,386	7,220	374,345
Charge for year	-	37,628	94,833	1,387,105
Eliminated on disposal	(17,799)	-	-	(17,799)
At 31 December 2022	<u>159,175</u>	<u>49,014</u>	<u>102,053</u>	<u>1,743,651</u>
Net book value				
At 31 December 2022	<u>278,237</u>	<u>8,884</u>	<u>14,589</u>	<u>2,557,985</u>
At 31 December 2021	<u>66,805</u>	<u>2,325</u>	<u>29,897</u>	<u>1,079,849</u>

Company

	Improvements to property £	Assets under construction £	Plant and machinery £	Motor vehicles £
Cost				
At 1 January 2022	-	815,158	164,070	-
Additions	1,965,258	-	143,332	11,440
Disposals	-	(815,158)	-	-
At 31 December 2022	<u>1,965,258</u>	<u>-</u>	<u>307,402</u>	<u>11,440</u>
Depreciation				
At 1 January 2022	-	-	81,381	-
Charge for year	115,603	-	119,539	2,080
Eliminated on disposal/reclassification	-	-	4,380	-
At 31 December 2022	<u>115,603</u>	<u>-</u>	<u>205,300</u>	<u>2,080</u>
Net book value				
At 31 December 2022	<u>1,849,655</u>	<u>-</u>	<u>102,102</u>	<u>9,360</u>
At 31 December 2021	<u>-</u>	<u>815,158</u>	<u>82,689</u>	<u>-</u>

Molecular Dimensions Limited (Registered number: 01794026)

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

11. Tangible fixed assets - continued

Company

	Fixtures and fittings £	Office equipment £	Computer equipment £	Totals £
Cost				
At 1 January 2022	227,733	2,325	12,407	1,221,693
Additions	81,013	1,464	-	2,202,507
Disposals	-	-	(12,407)	(827,565)
At 31 December 2022	<u>308,746</u>	<u>3,789</u>	<u>-</u>	<u>2,596,635</u>
Depreciation				
At 1 January 2022	155,817	-	-	237,198
Charge for year	-	1,678	-	238,900
Eliminated on disposal/reclassification	(117,609)	-	-	(113,229)
At 31 December 2022	<u>38,208</u>	<u>1,678</u>	<u>-</u>	<u>362,869</u>
Net book value				
At 31 December 2022	<u>270,538</u>	<u>2,111</u>	<u>-</u>	<u>2,233,766</u>
At 31 December 2021	<u>71,916</u>	<u>2,325</u>	<u>12,407</u>	<u>984,495</u>

12. Fixed asset investments

Company

	Shares in group undertakings £
Cost	
At 1 January 2022	7,837,681
Additions	11,198,589
At 31 December 2022	<u>19,036,270</u>
Net book value	
At 31 December 2022	<u>19,036,270</u>
At 31 December 2021	<u>7,837,681</u>

Molecular Dimensions Limited (Registered number: 01794026)

**Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022**

12. Fixed asset investments - continued

The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

Protein Ark Limited

Registered office: England
Nature of business: Dormant

Class of shares:	%
Ordinary	holding 100.00

Oeeey Limited

Registered office: England
Nature of business: Dormant

Class of shares:	%
Ordinary	holding 100.00

Lorne Laboratories Limited

Registered office: England
Nature of business: Dormant

Class of shares:	%
Ordinary	holding 100.00

BioServ UK Limited

Registered office: England
Nature of business: Dormant

Class of shares:	%
Ordinary	holding 100.00

Kalon Biological Limited

Registered office: England
Nature of business: Dormant

Class of shares:	%
Ordinary	holding 100.00

Clin-Tech Limited

Registered office: England
Nature of business: Dormant

Class of shares:	%
Ordinary	holding 100.00

Elkay Laboratory Products (UK) Limited

Registered office: England
Nature of business: Manufacturing

Class of shares:	%
Ordinary	holding 100.00

Medline Scientific Limited

Registered office: England
Nature of business: Manufacturing

Class of shares:	%
Ordinary	holding 100.00

Molecular Dimensions Limited (Registered number: 01794026)

**Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022**

12. Fixed asset investments - continued

Technival group Limited
Registered office: England
Nature of business: Services

Class of shares:	%
Ordinary	holding 100.00

Technival Limited
Registered office: England
Nature of business: Services

Class of shares:	%
Ordinary	holding 100.00

Anville Instrument Limited
Registered office: England
Nature of business: Services

Class of shares:	%
Ordinary	holding 100.00

Agar International Limited
Registered office: England
Nature of business: Manufacturing

Class of shares:	%
Ordinary	holding 100.00

Agar Scientific Limited
Registered office: England
Nature of business: Manufacturing

Class of shares:	%
Ordinary	holding 100.00

Acquisition

On 20 July 2022, Molecular Dimensions Limited acquired a new group, Agar International Limited and its trading subsidiary Agar Scientific Limited, a manufacturer and distributor of microscopy consumables and equipment for a consideration of £10.4m.

The post acquisition results have been consolidated in these financial statements.

Consideration	£ 10,398,589
Net assets acquired	(1,285,883)
Goodwill arising on acquisition	<u>9,112,702</u>

On 13 December 2022, Molecular Dimensions Limited acquired a new group, Technival Group Limited and its trading subsidiaries Technival Limited and Anville Instruments Limited, suppliers of equipment servicing and calibration services for a consideration of £0.8m.

Consideration	£ 800,000
Net assets acquired	(971,534)
Goodwill arising on acquisition	<u>(171,534)</u>

Molecular Dimensions Limited (Registered number: 01794026)

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

13. Stocks

	Group		Company	
	2022	2021	2022	2021
	£	£	£	£
Raw materials	381,312	256,782	339,917	186,650
Work-in-progress	52,100	85,563	20,000	85,563
Finished goods	<u>3,296,229</u>	<u>2,388,991</u>	<u>1,286,900</u>	<u>1,326,042</u>
	<u>3,729,641</u>	<u>2,731,336</u>	<u>1,646,817</u>	<u>1,598,255</u>

14. Debtors: amounts falling due within one year

	Group		Company	
	2022	2021	2022	2021
	£	£	£	£
Trade debtors	3,430,034	2,407,988	1,541,040	1,500,022
Amounts owed by group undertakings	751,922	2,621,779	751,922	493,921
Other debtors	367,214	809,791	245,544	284,974
VAT	343,729	-	407,920	517,226
Prepayments and accrued income	<u>242,286</u>	<u>187,104</u>	<u>169,049</u>	<u>98,292</u>
	<u>5,135,185</u>	<u>6,026,662</u>	<u>3,115,475</u>	<u>2,894,435</u>

15. Creditors: amounts falling due within one year

	Group		Company	
	2022	2021	2022	2021
	£	£	£	£
Trade creditors	2,262,024	1,639,575	936,715	648,457
Amounts owed to group undertakings	1,102,004	8,347,275	6,342,811	8,354,945
Tax	527,994	963,850	251,065	953,735
Social security and other taxes	683,843	543,520	388,326	376,345
Other creditors	729,161	519,884	485,915	469,175
Accruals and deferred income	<u>353,405</u>	<u>582,941</u>	<u>261,076</u>	<u>427,567</u>
	<u>5,658,431</u>	<u>12,597,045</u>	<u>8,665,908</u>	<u>11,230,224</u>

Finance lease and hire purchase liabilities are secured on the individual assets to which they relate.

16. Creditors: amounts falling due after more than one year

	Group		Company	
	2022	2021	2022	2021
	£	£	£	£
Other creditors	<u>18,167,919</u>	<u>17,177</u>	<u>16,406,491</u>	<u>-</u>

Molecular Dimensions Limited (Registered number: 01794026)

Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022

17. Leasing agreements

Minimum lease payments fall due as follows:

Group

	Non-cancellable operating leases	
	2022	2021
	£	£
Within one year	442,151	382,716
Between one and five years	736,827	917,584
In more than five years	426,559	70,833
	<u>1,605,537</u>	<u>1,371,133</u>

Company

	Non-cancellable operating leases	
	2022	2021
	£	£
Within one year	208,791	179,786
Between one and five years	668,652	685,797
In more than five years	426,559	407,782
	<u>1,304,002</u>	<u>1,273,365</u>

18. Provisions for liabilities

	Group		Company	
	2022	2021	2022	2021
	£	£	£	£
Deferred tax				
Accelerated capital allowances	<u>155,201</u>	<u>114,218</u>	<u>108,953</u>	<u>108,953</u>

Group

	Deferred tax
	£
Balance at 1 January 2022	114,218
Provided during year	<u>40,983</u>
Balance at 31 December 2022	<u>155,201</u>

Company

	Deferred tax
	£
Balance at 1 January 2022	<u>108,953</u>
Balance at 31 December 2022	<u>108,953</u>

19. Called up share capital

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2022	2021
			£	£
30	Ordinary	£1	<u>30</u>	<u>30</u>

Molecular Dimensions Limited (Registered number: 01794026)

**Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022**

20. Pension commitments

The Group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charge represents contributions payable by the Group to the fund and amounted to £117,098 (2021 - £104,294). Contributions totalling £29,007 (2021 - £3,172) were payable to the fund at the reporting date and are included in creditors.

21. Post balance sheet events

On 16 March 2023, Molecular Dimensions Limited acquired a new group, BB3 Holdings Limited and its trading subsidiary Sciquip Limited, a distributor of laboratory consumables and equipment for a consideration of £7.5m.

On 14 November 2023, Molecular Dimensions Limited acquired a new company Scientific Support Services limited for a consideration of £675k.

On 15 December 2023, Molecular Dimensions Limited acquired a new company Microm UK limited for a consideration of £200k.

On 05 January 2024, Molecular Dimensions Limited acquired a new company Labtech International limited for a consideration of £1.1m.

On 22 February 2024, Molecular Dimensions Limited acquired a new company Environmental Validation Services limited for a consideration of £750k.

22. Ultimate controlling party

The immediate parent undertaking is Anatrace Products LLC, a company registered in the USA. The ultimate parent company is Life Science Holdings LLC, a company registered in the USA. Life Science Holdings LLC is the smallest group for which group accounts are drawn up. The registered office of Life Science Holdings LLC is 6201 Trust Drive, Holland, Ohio 43528, United States of America.

Molecular Dimensions Limited (Registered number: 01794026)

**Notes to the Consolidated Financial Statements - continued
for the year ended 31 December 2022**

23. Reconciliation of (loss)/profit before taxation to cash generated from operations

	2022	2021
	£	£
(Loss)/profit before taxation	(781,177)	3,361,533
Depreciation charges	865,212	86,763
Amortisation charge	1,306,711	418,327
Finance costs	1,528	109,087
Finance income	(2,978)	(4)
	<u>1,389,296</u>	<u>3,975,706</u>
(Increase)/decrease in stocks	(998,305)	1,780,199
(Increase)/decrease in trade and other debtors	(8,035,448)	1,835,713
Increase/(decrease) in trade and other creditors	<u>22,565,940</u>	<u>(2,645,206)</u>
Cash generated from operations	<u><u>14,921,483</u></u>	<u><u>4,946,412</u></u>

24. Cash and cash equivalents

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2022

	31/12/22	1/1/22
	£	£
Cash and cash equivalents	<u>1,924,146</u>	<u>1,610,643</u>

Year ended 31 December 2021

	31/12/21	1/1/21
	£	£
Cash and cash equivalents	<u>1,610,643</u>	<u>482,067</u>

25. Analysis of changes in net funds

	At 1/1/22	Cash flow	At 31/12/22
	£	£	£
Net cash			
Cash at bank	<u>1,610,643</u>	<u>313,503</u>	<u>1,924,146</u>
	<u>1,610,643</u>	<u>313,503</u>	<u>1,924,146</u>
Total	1,610,643	313,503	1,924,146

The notes form part of these financial statements